Sarep­ta all-in on gene ther­a­py pipeline, adding 3 CNS treat­ments in $30M Lac­er­ta deal

Sarep­ta’s lead gene ther­a­py $SRPT may be on clin­i­cal hold, but the brash Duchenne mus­cu­lar dy­s­tro­phy com­pa­ny is con­tin­u­ing its deep dive in­to the field, hand­ing over $30 mil­lion in an eq­ui­ty in­vest­ment in Lac­er­ta in ex­change for a group of CNS ther­a­pies, in­clud­ing one pro­gram fo­cused on Pompe dis­ease.

The biotech re­port­ed the deal just af­ter mar­ket close on Wednes­day, along with a Q2 state­ment show­ing grow­ing sales vol­ume for Ex­ondys 51.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER